Evidence map›Paper›PMID 40909795›Full record

ArticleResearch square2025

Butyrate Modulates Intestinal Microbiome and Epithelial Function to Attenuate Irinotecan-induced GI Toxicity.

Stanley M Cheatham, Zayd Rehman, Mahshid Arastonejad, Yuesheng Zhang, David A Gewirtz, Hamid I Akbarali, Hisashi Harada, Natalie Luffman, Katarzyna M Tyc

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Stanley M CheathamDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, 23298, USA.
Zayd RehmanDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, 23298, USA.
Mahshid ArastonejadDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, 23298, USA.
Yuesheng ZhangDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, 23298, USA.
David A GewirtzDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, 23298, USA.
Hamid I AkbaraliDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, 23298, USA.ORCID https://orcid.org/0000-0003-1423-0774
Hisashi HaradaDepartment of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, 23298, USA.
Natalie LuffmanDepartment of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, 23298, USA.
Katarzyna M TycDepartment of Biostatistics, Virginia Commonwealth University, Richmond, 23298, USA.

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Renato Martins · 1985 to 2026
$51.0M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI JOLENE J WINDLE · 2014 to 2026
$13.8M
NCI NIH HHS P30 CA016059NIDA NIH HHS P30 DA033934
6 · The paper itself

Abstract

Chemotherapy-induced gastrointestinal toxicity is a significant dose-limiting complication for cancer treatment. Disruption of the gastrointestinal (GI) epithelial barrier function by several chemotherapeutic agents results in development of mucositis and diarrhea. Thus, maintaining barrier integrity may be of therapeutic benefit. Recent studies have shown the beneficial effects of the microbial metabolite butyrate, a short chain fatty acid (SCFA), on epithelial barrier integrity. In this current study, we tested the effect of oral butyrate on irinotecan-induced gastrointestinal (GI) toxicity in mice. Irinotecan dose-dependently reduced body weight and increased fecal water content. Nicotine-induced inward currents in ileum myenteric neurons were significantly increased in irinotecan treated mice consistent with enhanced GI motility. Loperamide reduced GI motility of irinotecan treated mice, however tolerance developed with chronic use, consistent with clinical findings of loperamide refractory diarrhea in patients. Oral butyrate improved epithelial permeability, prevented loss in stem cell marker,

Identifiers

PMID40909795
PMCPMC12408006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.